Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 939-943

  Jaakkola, Misa ^a   Rantanen, Virpi ^a   Grénman, Seija ^a   Kulmala, Jarmo ^a   Grénman, Reidar ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Chemosensitivity; In vitro; Paclitaxel; Vulvar carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CHEMOSENSITIVITY; CLONOGENIC ASSAY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; VULVAR NEOPLASMS;

EID: 0030939468     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Berek JS, Heaps JM, Fu YS, Juillard GJF and Hacker NF: Concurrent cisplatin and 5-fluorouraciI chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol 42: 197-201,1991.
2. Russell AH, Mesic JB, Scudder SA. Rosenberg PJ, Smith LH, Kinney WK, Townsend DE, Trelford JD,Taylor MH, Xukowski CE and McMahon KG: Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. Gynecol Oncol 47: 14-20,1992.
3. Koh W-J, Wallace III HJ, Greer BE, Cain J, Stelzer KJ, Russell KJ, Tamimi OK, Figge DC, Russell AH and Griffin TW: Combined radiotherapy and chemotherapy in the management of localregionally advanced vulvar cancer. Int J Radiation Oncology Biol Phys 26: 809-816,1993.
4. Wahlen SA, Slater JD, Wagner RJ, Wang WA, Keeney ED, Hocko JM, King A and Slater JM: Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva. Cancer 75: 2289-2294,1995.
5. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-2597,1990.
6. Manfredi JJ and Horwitz SB: Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-125,1984.
7. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565,1980.
8. Liebmann JE, Cook JA, Lipschultz C, league D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell Imes. BrJ Cancer 68: 1104-1109, 1993.
9. Eisenhauer EA. ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buscr K, Colombo N, Bacon M, santabarbara P, Onetto N, Winograd B and Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666,1994.
10. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Ruzdar AU, Frye DK and Hortobagyi GN: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
11. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY and Davidson M: Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP). Proc Am Soc Clin Oncol 14: 275,1995.
12. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Cross HM, Davilla F; Leimert J, Dhingra H, Raber MN, Krakoff IH and Hong WK: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993.
13. Forastiere AA: Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21(Suppl 8): 49-52,1994.
14. McGuire YVP. Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KV Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334: 1-6, 1996.
15. Grenman SE, Van Dyke DL, Worsham M3, England B, McClatchey KD, Hopkins M, Babu R, Grenman R and Carey TE: Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UM-SCV-1B. Int J Cancer 45: 920-927, 1990.
16. Worsham MJ, Van Dyke DL.Grénman SE, Grenman R, Hopkins MP, Roberts JA, Gasser KM, Schwartz DR and Carey TE: Consistent chromosome abnormalities in squamous cell carsinoma of the vulva. Genes Chrom Cancer 3: 420-432,1991.
17. Grenman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR and Carey TE: Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136,1989.
18. Rantanen V, Grénman S, Kulmala J and Grénman R: Comparative evaluation of cisplatin and carboplatin in endometrial adenocarcinoma cell lines. Br J Cancer 69: 482-486, 1994.
19. Pekkola-Heino K, Kulmala J, Grenman S, Carey TE and Grenman R: Radiation response of vulvar squamous cell carcinoma (UM-SCV1A, UM-SCV-1B, UMSCV-2 and A-431) cells in vitro. Cancer Res 49: 4876-4878, 1989.
20. Rantanen V, Grenman S, Kulmala J, Salmi T and Grenman R: Radiation sensitivity of endometrial carcinoma in vitro. Gynecol Oncol 44: 217-222, 1992.
21. Rantanen V, Grenman S, Kulmala J and Grénman R: The intrinsic radiosensitivity and sublethal damage repair capasity of five cervical carcinoma cell lines tested with the 96-well plate assay. J Cancer Res Clin Oncol 30-234,1995.
22. Grénman R, Burk D, Virolainen E, Wagner JG, Lichter AS and Carey TE: Radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma. Arch Otoraryngol Head Neck Surg 114: 427-431, 1988.
23. Kulmala J, Rantanen V, Pekkola-Heino K, Tuominen J and Grénman R: Dosimetry of irradiation models: the 96-well clonogenic assay for testing radiosensitivity of cell lines. Acta Oncol 34: 105-109, 1995.
24. Kelland LR and Abel G: Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450,1992.
25. Tishler RB, Geard CR, Hall EJ and Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497, 1992.
26. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
27. Elomaa L, Joensuu H, Kulmala J, Klemi P and Grénman R: Squamous cell carcinoma is highly sensitive to Taxol, a possible new radiation sensitizer. Acta Otolaryngol 115: 340-344, 1995.
28. Untch M, Sevin B-U, Perras JP, Angioli R, Unteh A, Hightower RD, Koehli O and Averette HE: Evaluation of paclitaxel (Taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53: 44-49, 1994.
29. Shinohara K and Nakano H: Interphase death and reproductive death in X-irradiated MOLT-4 cells. Radiat Res 135: 197-205, 1993.
30. Chang AY: Non-small cell lung cancer. In: Paclitaxel in cancer treatment. (W. P. McGuire and E. K. Rowinsky, Eds). New York, Marcel Dekker Inc., W5, pp 273-279.
31. Rantanen V, Grénman S, Kulmala J and Grénman R: Endometrial cancer cell lines are sensitive to paclitaxel. Anticancer Res 16: 475-480, 1996.
32. Engblom P, Rantanen V, Kulmala J and Grénman S: Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96well plate clonogenic assay. Anticancer Res 16:1743-1748,1996.
33. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, risherman JS, Christian MC, Canetta R, Onetto N, Hayn R and Arbuck SG: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute treatment referral center 9103. J Clin Oncol 11: 2405-2410, 1993.
34. Rowinsky EK and Donehower RC: Paclitaxel (Taxol). New Engl J Med 332: 1004-10147, 1995.
35. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, Cummings G and Al-Sarraf M: Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients witht advanced squamous cell cancers of the head and neck. Cancer 54: 811-814,1984.
36. Kirsten F, Atkinson KH, Coppleson JVM, Elliott PM, Green D, Houghton R, Murray JC, Russell P, Solomon HJ, Friedlander M, Swanson CE and Tattersall MHN: Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. Br J Obstet Gynecol 94: 583-588,1987.
37. Kelland LR and Tonkin KS: In vitro chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity. Eur J Cancer Clin Oncol 25: 1211-1218,1989.
38. Steren A, Sevin B-U, Perras J, Angioli R, Nguyen H, Guerra L, Koechli O and Averette HE: Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 48: 252-258,1993.
39. Liebmann J, Cook JA, Fisher J, Teague D and Mitchell JB: Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol®). Int J Radiation Oncology Biol Phys 29: 559-564, 1994.
40. Geard CR and Jones JM: Radiation and Taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 29: 565-569, 1994.
41. Jaakkola M, Rantanen V. Grénman S, Kulmala J and Grénman R: In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines. Cancer 77: 1940-1946, 1996.
42. Giard DJ, Aaronson SA, Torado GV, Arnstein P, Kersey JH, Dosik H, Parks WP: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid lines tumors. J Natl Cancer Inst 51: 1417-1423, 943.